Promethera Biosciences SA, of Mont-Saint-Guibert, Belgium, raised €10 million (US$11 million) in a series C extension that included major existing shareholders Vesalius Biocapital, SRIW, Fund+, MGI Global Fund (Mitsui & Co.), Boehringer Ingelheim Venture Fund and SMS Investments.